compounded semaglutide enforcement news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Semaglutide injections will no longer

Synergistic triple receptor engagement is the pharmacological basis for Retatrutide's distinct research position

This article examines current evidence on retatrutide's known side effects, its relationship to UTI risk, how to recognise UTI symptoms, and when to seek medical advice

Supports Metabolic Signaling Pathways Helps support pathways related to appetite regulation and metabolic balance

in patients with T2DM (38) found that continuous GLP-1 administration via a subcutaneous pump to raise serum GLP-1 levels from a mean of 9.7 pM at baseline to 282 pM over 6 weeks significantly reduced plasma glucose concentrations, improved glycated hemoglobin, and enhanced insulin sensitivity and -cell function compared to placebo, with no significant limiting side effects reported

In total, 15% of Americans say they have used a GLP-1 drug for weight loss at some point

When in doubt, submit a sample for independent purity testing before using the material in research